Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring <i>BRCA1/2</i> Alterations
This retrospective cohort study of patients with mCRPC and evidence of BRCA1/2 alterations found that approximately half of patients did not receive PARP inhibitors despite evidence of survival improvement in this population. These findings highlight the need to increase awareness of the survival data and access to life-prolonging therapies in patients with mCRPC.
Authors
- Vinay Mathew Thomas (ORCID: https://orcid.org/0000-0001-9916-730X)
- Sumati Gupta (ORCID: https://orcid.org/0000-0001-6271-0831)
- Irbaz Bin Riaz (ORCID: https://orcid.org/0000-0003-4249-0311)
- Yeonjung Jo (ORCID: https://orcid.org/0000-0002-1630-2957)
- Benjamin Louis Maughan (ORCID: https://orcid.org/0000-0002-0010-8551)
- Umang Swami (ORCID: https://orcid.org/0000-0003-3518-0411)
- Zeynep İrem Özay (ORCID: https://orcid.org/0000-0002-4827-9042)
- Georges Gebrael (ORCID: https://orcid.org/0000-0002-4085-6415)
- Edwin Lin (ORCID: https://orcid.org/0000-0002-3951-3976)
- Nicolas Sayegh (ORCID: https://orcid.org/0000-0003-1924-8148)
- Chadi Hage Chehade (ORCID: https://orcid.org/0009-0008-6735-5777)
- Soumyajit Roy (ORCID: https://orcid.org/0000-0002-4888-6117)
- Abigail Gordhamer
- Haoran Li (ORCID: https://orcid.org/0000-0001-9181-7400)
- Micah Ostrowski
- Ayana Srivastava (ORCID: https://orcid.org/0009-0002-9521-5436)
- Neeraj Agarwal
- Richard Ji
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
- The University of Kansas Cancer Center (US)
- University Hospitals Seidman Cancer Center (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-10-02
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.34968
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05